Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
You could win a cash prize of up to £25,000 when you play the Breakthrough T1D lottery. As well as the chance to win great prizes, you’ll also help fund our research to find a cure for type 1 diabetes.
Invite your friends, family, colleagues or clients to an exceptional black-tie event in the heart of London. Every ticket, every bid, every moment helps us move closer to a cure.
Our ambitious new roadmap is aimed at driving significant advancements in type 1 diabetes research, treatment, and care.
Join the type 1 diabetes community and come together, raising awareness and vital funds for T1D.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
JDRF has now rebranded to Breakthrough T1D. Our name has changed, our mission has not.
Home > News & events > News > JDRF researchers reprogramme donor type 1 pancreas cells to produce insulin
In a world-first, JDRF-funded Australian researchers have successfully turned an insulin gene back on by injecting a drug called GSK126 into pancreatic cells donated from one person with type 1 and two people without.
Insulin is made by beta cells in the pancreas. Our bodies stop being able to make beta cells when we are babies whether we have type 1 diabetes or not. This is because the insulin gene that makes them gets turned off by a molecule called EZH2.
GSK126 is an existing drug that stops EZH2 from working, which enables the genes for producing insulin to start working again – essentially turning them back on. This allows other cells in the pancreas to develop into insulin-producing beta cells. GSK126 is currently licensed by the FDA – the organisation that approves drugs in the US – so we know it is safe for humans.
When type 1 diabetes happens, the immune system attacks the beta cells, which means the body can’t produce its own insulin. The study’s lead researcher, Professor Sam El-Osta, said: “By the time someone is diagnosed with type 1 diabetes, much of their pancreatic beta cells have been totally destroyed by the immune system.” So, manipulating the insulin gene could allow people with type 1 to make their own beta cells again to replace those they have lost.
You may be familiar with our research that aims to produce beta cells from stem cells, which are a type of cell that can transform into many other cell types. Although this research is exciting, we still have a little way to go before it is a viable treatment for people with type 1.
So, how does this new drug compare to these beta cell therapies? Professor El-Osta said: “Our research shows vital insulin production after just two days of drug treatment when compared to three to four months with alternative approaches using stem cells. This non-surgical method has the added benefit that treatments are less vulnerable to the risks associated with transplants.”
It’s important to remember that the study only used cells from three people, so much larger projects are needed to confirm their results. But Professor El-Osta, said: “The discovery of the genetic barrier to insulin which can be unlocked by a drug is an important milestone and a step in the right direction for the path to accelerate cures.”
New data from Sana Biotechnology, in collaboration with Uppsala University Hospital in Sweden, shows that six months post-transplant, one person with type 1 diabetes (T1D) is successfully producing insulin and does not require immunosuppression.
US-based company Vertex have published promising figures from their cell therapy trial, showing advancements in stem cell research.
Breakthrough T1D has helped organise an event hosted by Tomislav Sokol titled ‘Accelerating Breakthroughs to Address Unmet Needs in Type 1 Diabetes.’
Professor David Baker, a Breakthrough T1D-funded researcher at the University of Washington, has been awarded a Nobel Prize in Chemistry.
Don’t miss out on the latest research, inspiring stories, tech news, upcoming events, and handy information on living well with type 1. Join us now and receive it all straight to your inbox.
It’s thanks to your dedication that we have funded great progress in type 1 cure, treatment and prevention research. Help us to continue our vital research.
